23 results
Thumbnail

D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria

Thumbnail

D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series

Thumbnail

D1.376 - Emerging inmunomodulatory agents for atopic dermatitis

Thumbnail

D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report

Thumbnail

D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis

Thumbnail

D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)

Thumbnail

D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow

Thumbnail

D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report

Thumbnail

D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis

Thumbnail

D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity

Thumbnail

D1.386 - Impact of dupilumab on allergen specific immunoglobulin E production

Thumbnail

D3.316 - Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Nis-Serbia

Thumbnail

D3.305 - Pediatric and Adult Responses to Fourth-Fold Antihistamine Doses: Insights into Efficacy and Safety

Thumbnail

D3.306 - Successful treatment of severe atopic dermatitis in teenage patient with hyper-IgE syndrome (STAT3 mutation)

Thumbnail

D3.307 - Experience with Systemic Emergent Therapies for Moderate-to-Severe Atopic Dermatitis: Insights from an Allergy and Clinical Immunology Department

Thumbnail

D3.308 - Frailty in elderly with C1 Inhibitor Hereditary Angioedema: first evidence from a monocentric ITACA cohort

Thumbnail

D3.309 - Challenges in HAE therapy in children

Thumbnail

D3.310 - Hereditary angioedema (HAE) with factor XIIa mutation successfully treated with icatibant as on-demand therapy and lanadelumab for long-term prophylaxis

Thumbnail

D3.311 - Screening for Hereditary Angioedema in Pediatric Patients with Autoinflammatory Diseases and Chronic Abdominal Pain

Thumbnail

D3.312 - Lymphatic supplementation improves atopic dermatitis in dogs